MedTrace Logo

Tranexamic Acid Infusion During Elective Spine Surgery

NCT04312880 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2020-08-12

No results posted yet for this study

Summary

Tranexamic acid (TXA) is an agent that has been shown to be safe and effective to reduce blood loss in surgical procedures. The purpose of the study is to assess the effect of transexamic on elective decompressive lumbar spine surgery with and without fusion.

Conditions

  • Spine Surgery

Interventions

DRUG

Tranexamic Acid

IV and topical form of TXA will be administered to patients in the respective groups.

Sponsors & Collaborators

  • Albany Medical College

    lead OTHER

Principal Investigators

  • James Lawrence, MD · Attending Surgeon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-01-01
Completion
2021-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312880 on ClinicalTrials.gov